Prospera Financial Services Inc Trims Stake in Cencora, Inc. $COR

Prospera Financial Services Inc reduced its holdings in Cencora, Inc. (NYSE:COR) by 11.8% during the second quarter, Holdings Channel.com reports. The fund owned 8,881 shares of the company’s stock after selling 1,189 shares during the quarter. Prospera Financial Services Inc’s holdings in Cencora were worth $2,663,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of COR. Atlantic Edge Private Wealth Management LLC increased its position in shares of Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after purchasing an additional 35 shares during the last quarter. Costello Asset Management INC bought a new stake in Cencora during the first quarter valued at approximately $28,000. University of Texas Texas AM Investment Management Co. bought a new stake in Cencora during the first quarter valued at approximately $39,000. Caitong International Asset Management Co. Ltd purchased a new position in Cencora in the 2nd quarter worth approximately $61,000. Finally, ANTIPODES PARTNERS Ltd bought a new position in shares of Cencora in the 2nd quarter worth $61,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on COR. Mizuho lifted their price objective on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. UBS Group raised their price target on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research report on Friday. Wells Fargo & Company lifted their price target on Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 13th. Robert W. Baird upped their price objective on Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, Morgan Stanley set a $330.00 price objective on Cencora and gave the company an “equal weight” rating in a report on Wednesday, July 16th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $355.91.

Insider Activity at Cencora

In other news, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares in the company, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the sale, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 41,544 shares of company stock valued at $12,230,941 in the last quarter. Corporate insiders own 10.80% of the company’s stock.

Cencora Price Performance

Shares of NYSE:COR opened at $364.40 on Tuesday. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The stock has a market cap of $70.65 billion, a PE ratio of 37.49, a PEG ratio of 1.56 and a beta of 0.63. The company’s fifty day moving average is $315.73 and its 200 day moving average is $300.12. Cencora, Inc. has a 52 week low of $223.92 and a 52 week high of $366.00.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The firm had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period last year, the firm earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be paid a $0.60 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s payout ratio is presently 30.19%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.